Bayer has granted the non-exclusive rights to Sun Pharma to market and distribute a second brand of Finerenone under the brand name Lyvelsa
Keytruda is the first and only anti-PD-1 therapy approved in combination with chemoradiotherapy for these patients
Varenicline Tablets (RLD Chantix) had estimated annual sales of US $412 million in the US
Doxazosin tablets are indicated for the treatment of hypertension, to lower blood pressure
Bromfenac Ophthalmic Solution, 0.07% is the generic equivalent of Prolensa Ophthalmic Solution, 0.07%, of Bausch & Lomb
Submission based on positive results from global phase 3 study demonstrating overall survival benefit of TIVDAK over chemotherapy
TALZENNA is the first and only PARP inhibitor approved in combination with standard of care XTANDI for mCRPC patients in the European Union
Dapagliflozin and Saxagliptin Tablets (RLD Qtern) had estimated annual sales of US $5 million in the US
Subscribe To Our Newsletter & Stay Updated
